Form 8-K - Current report:
SEC Accession No. 0001193125-25-071325
Filing Date
2025-04-02
Accepted
2025-04-02 16:10:00
Documents
15
Period of Report
2025-04-02
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d928406d8k.htm   iXBRL 8-K 40901
2 EX-3.1 d928406dex31.htm EX-3.1 19649
3 EX-3.2 d928406dex32.htm EX-3.2 117567
  Complete submission text file 0001193125-25-071325.txt   327405

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA itci-20250402.xsd EX-101.SCH 2894
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20250402_lab.xml EX-101.LAB 17979
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20250402_pre.xml EX-101.PRE 11287
17 EXTRACTED XBRL INSTANCE DOCUMENT d928406d8k_htm.xml XML 3695
Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 25804510
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)